Basiliximab in Moderate to Severe Ulcerative Colitis
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, effectiveness and pharmacokinetics of two
levels of intravenous basiliximab in ulcerative colitis, compared to placebo.